12 月2 日,公司公告先必新舌下片获NMPA 批准在中国上市,用于治疗AIS。此外,公司在国谈中先必新降价温和,新品成功纳入;叠加新品陆续获批带来增量,我们看好公司业绩复苏。我们亦看好公司的差异化创新早研管线,其中的领先者颇具全球潜力。维持“买入”。疗效显著给药便捷,有望拓宽使用场景先必新舌下片在治疗AIS 的III 期临床TASTE-SL 研究中取得显著疗效,其mRS 0~1 分比例显著优于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.